Add BrightSurf on Google Email

Korea University College of Medicine’s Vaccine Innovation Center selected as lead institution for 2025 Korea-ARPA-H Health Security Project

The Vaccine Innovation Center at Korea University College of Medicine has been selected as the lead institution for a health security research initiative focused on developing broad-spectrum antiviral agents and combination therapies to prevent severe disease in future pandemics. The project aims to create advanced therapeutics capable...

Randomized trials show no evidence of non-specific vaccine effects

A comprehensive review of over 25 years of research on non-specific vaccine effects reveals no evidence to support the claim that vaccines protect against diseases other than the ones they are designed to prevent. The study, which analyzed 13 randomized trials, shows that prominent researchers have systematically over-interpreted the f...

SourceAarhus University·JournalVaccine·TypeMeta-analysis·DateNov 13, 2025

MIT research finds particles that enhance mRNA delivery could reduce vaccine dosage and costs

Researchers have developed particles that can deliver an effective immune response at a much lower dose than traditional mRNA vaccines. The new particles, called AMG1541, use cyclic structures and ester groups to enhance mRNA delivery and improve biodegradability. This could potentially reduce vaccine costs and side effects.

SourceMassachusetts Institute of Technology·JournalNature Nanotechnology·DateNov 7, 2025

Safer, more effective vaccines with new mRNA vaccine technology

Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.

Two-dose recombinant shingles vaccine is effective even accounting for prior receipt of live shingles vaccine

The recombinant shingles vaccine achieved over 50% effectiveness against any herpes zoster outcome in both older and immunocompromised adults. The study suggests individuals previously vaccinated with live zoster should be revaccinated with two doses of RZV to maintain protection.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateOct 13, 2025

New vaccine shows promise against typhoid and invasive salmonella in first human trial

A Phase 1 clinical trial has successfully tested a new vaccine against typhoid fever and invasive non-typhoidal Salmonella, demonstrating strong immune responses in healthy adults. The vaccine triggered balanced immune defenses and showed potential for whole-body protection against Salmonella.

SourceUniversity of Maryland School of Medicine·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateOct 8, 2025

Qdenga vaccine shows effectiveness against dengue under real-world conditions during Brazil’s 2024 outbreak

The Qdenga vaccine provided a 50% reduction in symptomatic dengue cases and 68% hospitalization rate after one dose, with protection lasting three months. The study's findings have significant implications for public health decision-making, particularly in non-endemic regions where local transmission is increasing.

SourceInstitut de Recerca Sant Pau (Sant Pau Research Institute)·JournalThe Lancet Infectious Diseases·TypeObservational study·DateOct 1, 2025

VCU Massey Comprehensive Cancer Center joins leading cancer research centers to reinforce importance of HPV vaccination to prevent cancer

The VCU Massey Comprehensive Cancer Center, along with 61 other NCI-Designated Cancer Centers, has endorsed a joint statement urging healthcare systems and the public to prioritize HPV vaccination for cancer prevention. HPV vaccination is safe and effective in preventing six types of cancers caused by HPV infection.

SourceVirginia Commonwealth University·TypeNews article·DateSep 25, 2025

A chemically modified STn glycoconjugate vaccine with enhanced antitumor immunity

A chemically modified STn glycoconjugate vaccine has been developed with enhanced antitumor immunity, demonstrating substantial resistance to enzymatic degradation and inducing potent T-cell responses. The vaccine induces functional antibodies capable of initiating both CDC and ADCC against STn-positive tumor cells.

SourceKeAi Communications Co., Ltd.·JournalGlycoscience & Therapy·TypeExperimental study·DateSep 12, 2025

Even healthy children can be severely affected by RSV

A comprehensive registry study in Sweden found that healthy, full-term babies under three months old are at risk of severe illness from RSV. The study highlights several risk factors, including birth weight and sibling age, which increase the risk of needing intensive care or dying.

SourceKarolinska Institutet·JournalThe Lancet Regional Health - Europe·TypeObservational study·DateSep 9, 2025

Internationally recognized malaria researcher Stefan Kappe, Ph.D., appointed new director of the UM School of Medicine's Center for Vaccine Development and Global Health

Stefan Kappe, a leading expert in genetic engineering of parasites, has been appointed as the new Director of the Center for Vaccine Development and Global Health at UM School of Medicine. He will focus on developing genetically engineered live-attenuated pathogens to combat malaria infection.

High-volume antibody testing platform could accelerate disease research and treatment development

Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalScience Translational Medicine·TypeExperimental study·DateSep 3, 2025

Vaccines trigger rapid lymph node responses

Researchers discovered that vaccines induce changes in stromal cells of draining lymph nodes within hours, priming the landscape for immune responses. Different vaccines activate lymph node stromal cells differently, with some inducing specific effects on lymphatic endothelial cells.

SourceUniversity of Turku·JournalScience Immunology·DateAug 18, 2025

How AI could speed the development of RNA vaccines and other RNA therapies

Researchers used machine-learning models to design nanoparticles that can deliver RNA to cells more efficiently. The approach accelerated the identification of optimal ingredient mixtures in lipid nanoparticles, leading to better delivery vehicles for RNA vaccines and mRNA therapies. This could dramatically speed up the development of ...

SourceMassachusetts Institute of Technology·JournalNature Nanotechnology·DateAug 15, 2025

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.

Mucosal adenovirus vaccine Ad5-XBB.1.5 boosting elicits nasal IgA and transiently prevents JN.1 wave infection for less than 6 months in real-world settings

The study found that the vaccine effectively induces a rapid mucosal and systemic IgA response, but its protective effect against emerging variants like JN.1 appears short-lived. The results highlight the need for improved mucosal vaccine platforms capable of inducing durable immunity.

SourceTsinghua University Press·JournalhLife·DateJul 29, 2025

The Vaccine Innovation Center of Korea University's College of Medicine successfully held a special seminar with Professor Pierre Van Damme

Renowned vaccine expert Pierre Van Damme shared his experience leading over 500 clinical trials and establishing Vaccinopolis, a global research hub for vaccine clinical trials. The Vaccine Innovation Center of Korea University's College of Medicine aims to expand global cooperation in vaccine R&D through special seminars.

Improving T cell responses to vaccines

Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.

SourceUniversity of Pennsylvania·JournalScience Immunology·TypeExperimental study·DateJun 6, 2025

Illinois researchers explore COVID-19 vaccine attitudes and motivations, finding common values

A new study by University of Illinois researchers highlights the need for flexible approaches to reach diverse audiences with disease prevention strategies. The findings underscore that there is no one-size-fits-all solution to public health challenges, and understanding people's value systems can help inform policy recommendations.

SourceUniversity of Illinois College of Agricultural, Consumer and Environmental Sciences·JournalJournal of Medical Case Reports·TypeCase study·DateMay 20, 2025